Aligos Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Aligos Therapeutics Inc ALGS.OQ reported a quarterly adjusted loss of $1.53​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 80 cents. The mean expectation of four analysts for the quarter was for a loss of $2.36 per share. Wall Street expected results to range from $-2.67 to $-2.02 per share.

• Revenue fell 9% to $965.00 thousand from a year ago; analysts expected $433.33 thousand.

• Aligos Therapeutics Inc's reported EPS for the quarter was a loss of $1.53​.

• The company reported a quarterly loss of $15.86 million.

• Aligos Therapeutics Inc shares had risen by 9.7% this quarter and lost 80.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Aligos Therapeutics Inc is $65.00, about 87.6% above its last closing price of $8.04

This summary was machine generated from LSEG data August 7 at 01:12 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)